Join the Oncology Voice Network. Join for Free
How Compliance Builds Trust in Cancer Care

How Compliance Builds Trust in Cancer Care


Share This Article


Summary

Discover how trust, culture, and teamwork lift oncology drug development to new heights.

In this episode of the Oncology Voice Network Podcast, Host Dr. Kirk Shepard interviews Tina Beamon, a respected legal and compliance leader whose career spans pharma, biotech, and patient advocacy. Drawing from firsthand experience, Tina shares her journey from editing patient stories at the height of the AIDS epidemic to helping launch life-changing oncology drugs. Together, they discuss the real difference between legal and compliance, reveal how compliance becomes a strategic advantage in drug development, and explain why an effective compliance program is all about organizational culture. Tina gives practical advice for early-stage companies and highlights how compliance empowers medical and commercial teams to collaborate safely and creatively—always with patients at the center. Learn why compliance should be at the table in every conversation, how to build trust with patient advocacy groups, and how leadership shapes the culture that patients rely on.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment frameworks in oncology: championing concordance through shared standards
OVN Avatar M. Bertagnolli and J. Tabernero

Value assessment frameworks in oncology: championing concordance through shared standards

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Explore OVN